Illustrating and homology modeling the proteins of the Zika virus

F1000Research

Volumn 5, Issue , 2016, Pages

  Ekins, Sean ^a,b,c   Liebler, John ^d   Neves, Bruno J ^e   Lewis, Warren G ^f   Coffee, Megan ^g   Bienstock, Rachelle ^h   Southan, Christopher ⁱ   Andrade, Carolina H ^e  

^a Collaborations in Chemistry ^*  (United States)

^b Collaborations Pharmaceuticals Inc ^*  (United States)

^c Collaborative Drug Discovery Inc ^*  (United States)

^d Art of the Cell   (United States)

^e FEDERAL UNIVERSITY OF GOIÁS   (Brazil)

^f WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g INTERNATIONAL RESCUE COMMITTEE   (United States)

^h RJB Computational Modeling LLC   (United States)

ⁱ UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN E; GLYCOPROTEIN M; NONSTRUCTURAL PROTEIN 1; NONSTRUCTURAL PROTEIN 4A; NONSTRUCTURAL PROTEIN 4B; NONSTRUCTURAL PROTEIN 5; PEPTIDASE S7; PROPEPTIDE; PROTEIN DEXDC; PROTEIN E STEM; PROTEIN FTSJ; PROTEIN HELICC; PROTEIN NS2A; PROTEIN NS2B; UNCLASSIFIED DRUG; VIRAL PROTEIN;

AMINO ACID SEQUENCE; ARTICLE; COMPUTER MODEL; CRYSTAL STRUCTURE; DENGUE VIRUS; MATHEMATICAL COMPUTING; NONHUMAN; PROTEIN GLYCOSYLATION; PROTEIN STRUCTURE; VIRION; VIRUS CAPSID; ZIKA VIRUS;

EID: 85010908777     PISSN: 20461402     EISSN: 1759796X     Source Type: Journal    
DOI: 10.12688/F1000RESEARCH.8213.2     Document Type: Article

References (121)

1. Mlera L, Melik W, Bloom ME: The role of viral persistence in flavivirus biology. Pathog Dis. 2014; 71(2): 137-63.
2. Pierson TC, Kielian M: Flaviviruses: braking the entering. Curr Opin Virol. 2013; 3(1): 3-12.
3. Fauci AS, Morens DM: Zika Virus in the Americas-Yet Another Arbovirus Threat. N Engl J Med. 2016; 374(7): 601-4.
4. Ekins S, Mietchen D, Coffee M, et al.: Open drug discovery for the Zika virus [version 1; referees: awaiting peer review]. F1000Res. 2016; 5: 150.
5. Martines RB, Bhatnagar J, Keating MK, et al.: Notes from the Field: Evidence of Zika Virus Infection in Brain and Placental Tissues from Two Congenitally Infected Newborns and Two Fetal Losses-Brazil, 2015. MMWR Morb Mortal Wkly Rep. 2016; 65(6): 159-60.
6. Mlakar J, Korva M, Tul N, et al.: Zika Virus Associated with Microcephaly. N Engl J Med. 2016.
7. Rubin EJ, Greene MF, Baden LR: Zika Virus and Microcephaly. N Engl J Med. 2016.
8. Heymann DL, Hodgson A, Sall AA, et al.: Zika virus and microcephaly: why is this situation a PHEIC? Lancet. 2016; 387(10020): 719-21.
9. Bell TM, Field EJ, Narang HK: Zika virus infection of the central nervous system of mice. Arch Gesamte Virusforsch. 1971; 35(2): 183-93.
10. Vervaeke P, Alen M, Noppen S, et al.: Sulfated Escherichia coli K5 polysaccharide derivatives inhibit dengue virus infection of human microvascular endothelial cells by interacting with the viral envelope protein E domain III. PLoS One. 2013; 8(8): e74035.
11. Hamel R, Dejarnac O, Wichit S, et al.: Biology of Zika Virus Infection in Human Skin Cells. J Virol. 2015; 89(17): 8880-96.
12. Anon. Zika and Sexual Transmission. 2016.
13. Oduyebo T, Petersen EE, Rasmussen SA, et al.: Update: Interim Guidelines for Health Care Providers Caring for Pregnant Women and Women of Reproductive Age with Possible Zika Virus Exposure-United States, 2016. MMWR Morb Mortal Wkly Rep. 2016; 65(5): 122-7.
14. Musso D, Nhan T, Robin E, et al.: Potential for Zika virus transmission through blood transfusion demonstrated during an outbreak in French Polynesia, November 2013 to February 2014. Euro Surveill. 2014; 19(14). pii: 20761.
15. Aubry M, Richard V, Green J, et al.: Inactivation of Zika virus in plasma with amotosalen and ultraviolet A illumination. Transfusion. 2016; 56(1): 33-40.
16. Gyurech D, Schilling J, Schmidt-Chanasit J, et al.: False positive dengue NS1 antigen test in a traveller with an acute Zika virus infection imported into Switzerland. Swiss Med Wkly. 2016; 146: w14296.
17. Faye O, Freire CC, Iamarino A, et al.: Molecular evolution of Zika virus during its emergence in the 20th century. PLoS Negl Trop Dis. 2014; 8(1): e2636.
18. Alen MM, Kaptein SJ, De Burghgraeve T, et al.: Antiviral activity of carbohydratebinding agents and the role of DC-SIGN in dengue virus infection. Virology. 2009; 387(1): 67-75.
19. Lei Y, Yu H, Dong Y, et al.: Characterization of N-Glycan Structures on the Surface of Mature Dengue 2 Virus Derived from Insect Cells. PLoS One. 2015; 10(7): e0132122.
20. Nishikawa I, Nakajima Y, Ito M, et al.: Computational prediction of O-linked glycosylation sites that preferentially map on intrinsically disordered regions of extracellular proteins. Int J Mol Sci. 2010; 11(12): 4991-5008.
21. Li Z, Khaliq M, Zhou Z, et al.: Design, synthesis, and biological evaluation of antiviral agents targeting flavivirus envelope proteins. J Med Chem. 2008; 51(15): 4660-71.
22. Poh MK, Yip A, Zhang S, et al.: A small molecule fusion inhibitor of dengue virus. Antiviral Res. 2009; 84(3): 260-6.
23. Wang QY, Patel SJ, Vangrevelinghe E, et al.: A small-molecule dengue virus entry inhibitor. Antimicrob Agents Chemother. 2009; 53(5): 1823-31.
24. Mayhoub AS, Khaliq M, Kuhn RJ, et al.: Design, synthesis, and biological evaluation of thiazoles targeting flavivirus envelope proteins. J Med Chem. 2011; 54(6): 1704-14.
25. Schmidt AG, Lee K, Yang PL, et al.: Small-molecule inhibitors of dengue-virus entry. PLoS Pathog. 2012; 8(4): e1002627.
26. Zhou Z, Khaliq M, Suk JE, et al.: Antiviral compounds discovered by virtual screening of small-molecule libraries against dengue virus E protein. ACS Chem Biol. 2008; 3(12): 765-75.
27. Stahla-Beek HJ, April DG, Saeedi BJ, et al.: Identification of a novel antiviral inhibitor of the flavivirus guanylyltransferase enzyme. J Virol. 2012; 86(16): 8730-9.
28. Behnam MA, Nitsche C, Boldescu V, et al.: The Medicinal Chemistry of Dengue Virus. J Med Chem. 2016.
29. Vincetti P, Caporuscio F, Kaptein S, et al.: Discovery of Multitarget Antivirals Acting on Both the Dengue Virus NS5-NS3 Interaction and the Host Src/Fyn Kinases. J Med Chem. 2015; 58(12): 4964-75.
30. Shum D, Smith JL, Hirsch AJ, et al.: High-content assay to identify inhibitors of dengue virus infection. Assay Drug Dev Technol. 2010; 8(5): 553-70.
31. Crance JM, Scaramozzino N, Jouan A, et al.: Interferon, ribavirin, 6-azauridine and glycyrrhizin: antiviral compounds active against pathogenic flaviviruses. Antiviral Res. 2003; 58(1): 73-9.
32. Raska K Jr, Zedeck MS, Welch AD: Relationship between the metabolic effects and the pregnancy-interrupting property of 6-azauridine in mice. Biochem Pharmacol. 1966; 15(12): 2136-8.
33. Kochhar DM, Penner JD, Knudsen TB: Embryotoxic, teratogenic, and metabolic effects of ribavirin in mice. Toxicol Appl Pharmacol. 1980; 52(1): 99-112.
34. Entrican G: Immune regulation during pregnancy and host-pathogen interactions in infectious abortion. J Comp Pathol. 2002; 126(2-3): 79-94.
35. Blatt J, Farag S, Corey SJ, et al.: Expanding the scope of drug repurposing in pediatrics: the Children's Pharmacy Collaborative. Drug Discov Today. 2014; 19(11): 1696-8.
36. Klein DE, Choi JL, Harrison SC: Structure of a dengue virus envelope protein late-stage fusion intermediate. J Virol. 2013; 87(4): 2287-93.
37. Modis Y, Ogata S, Clements D, et al.: A ligand-binding pocket in the dengue virus envelope glycoprotein. Proc Natl Acad Sci U S A. 2003; 100(12): 6986-91.
38. Wu J, Bera AK, Kuhn RJ, et al.: Structure of the Flavivirus helicase: implications for catalytic activity, protein interactions, and proteolytic processing. J Virol. 2005; 79(16): 10268-77.
39. Geiss BJ, Thompson AA, Andrews AJ, et al.: Analysis of flavivirus NS5 methyltransferase cap binding. J Mol Biol. 2009; 385(5): 1643-54.
40. Zhang Y, Corver J, Chipman PR, et al.: Structures of immature flavivirus particles. EMBO J. 2003; 22(11): 2604-13.
41. Brecher M, Chen H, Li Z, et al.: Identification and Characterization of Novel Broad-Spectrum Inhibitors of the Flavivirus Methyltransferase. ACS Infect Dis. 2015; 1(8): 340-349.
42. Akey DL, Brown WC, Konwerski JR, et al.: Use of massively multiple merged data for low-resolution S-SAD phasing and refinement of flavivirus NS1. Acta Crystallogr D Biol Crystallogr. 2014; 70(Pt 10): 2719-29.
43. Zhang W, Kaufmann B, Chipman PR, et al.: Membrane curvature in flaviviruses. J Struct Biol. 2013; 183(1): 86-94.
44. Aleshin AE, Shiryaev SA, Strongin AY, et al.: Structural evidence for regulation and specificity of flaviviral proteases and evolution of the Flaviviridae fold. Protein Sci. 2007; 16(5): 795-806.
45. Kuno G, Chang GJ, Tsuchiya KR, et al.: Phylogeny of the genus Flavivirus. J Virol. 1998; 72(1): 73-83.
46. Anon. BLAST.
47. Altschul SF, Gish W, Miller W, et al.: Basic local alignment search tool. J Mol Biol. 1990; 215(3): 403-10.
48. Baronti C, Piorkowski G, Charrel RN, et al.: Complete coding sequence of Zika virus from a French polynesia outbreak in 2013. Genome Announc. 2014; 2(3): pii: e00500-14.
49. Benson DA, Cavanaugh M, Clark K, et al.: GenBank. Nucleic Acids Res. 2013; 41(Database issue): D36-42.
50. Biasini M, Bienert S, Waterhouse A, et al.: SWISS-MODEL: modelling protein tertiary and quaternary structure using evolutionary information. Nucleic Acids Res. 2014; 42(Web Server issue): W252-8.
51. Bordoli L, Kiefer F, Arnold K, et al.: Protein structure homology modeling using SWISS-MODEL workspace. Nat Protoc. 2009; 4(1): 1-13.
52. Benkert P, Tosatto SC, Schomburg D: QMEAN: A comprehensive scoring function for model quality assessment. Proteins. 2008; 71(1): 261-77.
53. Benkert P, Künzli M, Schwede T: QMEAN server for protein model quality estimation. Nucleic Acids Res. 2009; 37(Web Server issue): W510-4.
54. Anon. The Structure Analysis and Verification Server.
55. Anon. PROCHECK and PROCHECK-NMR.
56. Anon. N-GlycoSite.
57. Anon. GlycoEP.
58. Chauhan JS, Rao A, Raghava GP: In silico platform for prediction of N-, O-and C-glycosites in eukaryotic protein sequences. PLoS One. 2013; 8(6): e67008.
59. Anon. NetNGlyc.
60. Kuhn RJ, Zhang W, Rossmann MG, et al.: Structure of dengue virus: implications for flavivirus organization, maturation, and fusion. Cell. 2002; 108(5): 717-725.
61. Lu G, Gong P: Crystal Structure of the full-length Japanese encephalitis virus NS5 reveals a conserved methyltransferase-polymerase interface. PLoS Pathog. 2013; 9(8): e1003549.
62. Zhou Y, Ray D, Zhao Y, et al.: Structure and function of flavivirus NS5 methyltransferase. J Virol. 2007; 81(8): 3891-903.
63. Xu T, Sampath A, Chao A, et al.: Structure of the Dengue virus helicase/nucleoside triphosphatase catalytic domain at a resolution of 2.4 Å. J Virol. 2005; 79(16): 10278-88.
64. Mancini EJ, Assenberg R, Verma A, et al.: Structure of the Murray Valley encephalitis virus RNA helicase at 1.9 Angstrom resolution. Protein Sci. 2007; 16(10): 2294-300.
65. Hammamy MZ, Haase C, Hammami M, et al.: Development and characterization of new peptidomimetic inhibitors of the West Nile virus NS2B-NS3 protease. ChemMedChem. 2013; 8(2): 231-41.
66. Akey DL, Brown WC, Dutta S, et al.: Flavivirus NS1 structures reveal surfaces for associations with membranes and the immune system. Science. 2014; 343(6173): 881-5.
67. Zhang X, Ge P, Yu X, et al.: Cryo-EM structure of the mature dengue virus at 3.5-Å resolution. Nat Struct Mol Biol. 2013; 20(1): 105-10.
68. Li L, Lok SM, Yu IM, et al.: The flavivirus precursor membrane-envelope protein complex: structure and maturation. Science. 2008; 319(5871): 1830-4.
69. Dokland T, Walsh M, Mackenzie JM, et al.: West Nile virus core protein; tetramer structure and ribbon formation. Structure. 2004; 12(7): 1157-63.
70. Luca VC, AbiMansour J, Nelson CA, et al.: Crystal structure of the Japanese encephalitis virus envelope protein. J Virol. 2012; 86(4): 2337-46.
71. Arnold K, Bordoli L, Kopp J, et al.: The SWISS-MODEL workspace: a web-based environment for protein structure homology modelling. Bioinformatics. 2006; 22(2): 195-201.
72. Kiefer F, Arnold K, Künzli M, et al.: The SWISS-MODEL Repository and associated resources. Nucleic Acids Res. 2009; 37(Database issue): D387-92.
73. Guex N, Peitsch MC, Schwede T: Automated comparative protein structure modeling with SWISS-MODEL and Swiss-PdbViewer: a historical perspective. Electrophoresis. 2009; 30(Suppl 1): S162-73.
74. Kokernot RH, Smithburn KC, Muspratt J, et al.: Studies on arthropod-borne viruses of Tongaland. VIII. Spondweni virus, an agent previously unknown, isolated from Taeniorhynchus (Mansonioides) uniformis. S Afr J Med Sci. 1957; 22(2-3): 103-12.
75. Tognarelli J, Ulloa S, Villagra E, et al.: A report on the outbreak of Zika virus on Easter Island, South Pacific, 2014. Arch Virol. 2016; 161(3): 665-8.
76. Bessaud M, Pastorino BA, Peyrefitte CN, et al.: Functional characterization of the NS2B/NS3 protease complex from seven viruses belonging to different groups inside the genus Flavivirus. Virus Res. 2006; 120(1-2): 79-90.
77. Anon. VIZIER.
78. Bollati M, Alvarez K, Assenberg R, et al.: Structure and functionality in flavivirus NS-proteins: perspectives for drug design. Antiviral Res. 2010; 87(2): 125-48.
79. Parsy CC, Alexandre FR, Bidau V, et al.: Discovery and structural diversity of the hepatitis C virus NS3/4A serine protease inhibitor series leading to clinical candidate IDX320. Bioorg Med Chem Lett. 2015; 25(22): 5427-36.
80. Jiang Y, Andrews SW, Condroski KR, et al.: Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease. J Med Chem. 2014; 57(5): 1753-69.
81. Sheng XC, Casarez A, Cai R, et al.: Discovery of GS-9256: a novel phosphinic acid derived inhibitor of the hepatitis C virus NS3/4A protease with potent clinical activity. Bioorg Med Chem Lett. 2012; 22(3): 1394-6.
82. Schoenfeld RC, Bourdet DL, Brameld KA, et al.: Discovery of a novel series of potent non-nucleoside inhibitors of hepatitis C virus NS5B. J Med Chem. 2013; 56(20): 8163-82.
83. Kazmierski WM, Hamatake R, Duan M, et al.: Discovery of novel urea-based hepatitis C protease inhibitors with high potency against protease-inhibitorresistant mutants. J Med Chem. 2012; 55(7): 3021-6.
84. Rosenquist Å, Samuelsson B, Johansson PO, et al.: Discovery and development of simeprevir (TMC435), a HCV NS3/4A protease inhibitor. J Med Chem. 2014; 57(5): 1673-93.
85. Cummings MD, Lin TI, Hu L, et al.: Discovery and early development of TMC647055, a non-nucleoside inhibitor of the hepatitis C virus NS5B polymerase. J Med Chem. 2014; 57(5): 1880-92.
86. Link JO, Taylor JG, Xu L, et al.: Discovery of ledipasvir (GS-5885): a potent, once-daily oral NS5A inhibitor for the treatment of hepatitis C virus infection. J Med Chem. 2014; 57(5): 2033-46.
87. Zhang Y: I-TASSER.
88. Zhang Y: I-TASSER server for protein 3D structure prediction. BMC Bioinformatics. 2008; 9: 40.
89. Yang J, Yan R, Roy A, et al.: The I-TASSER Suite: protein structure and function prediction. Nat Methods. 2015; 12(1): 7-8.
90. Noble CG, Lim SP, Chen YL, et al.: Conformational flexibility of the Dengue virus RNA-dependent RNA polymerase revealed by a complex with an inhibitor. J Virol. 2013; 87(9): 5291-5295.
91. Flower DR: Bioinformatics for vaccinology. Chichester: Wiley-Blackwell, 2008.
92. Du H, Brender JR, Zhang J, et al.: Protein structure prediction provides comparable performance to crystallographic structures in docking-based virtual screening. Methods. 2015; 71: 77-84.
93. Levoin N, Calmels T, Krief S, et al.: Homology Model Versus X-ray Structure in Receptor-based Drug Design: A Retrospective Analysis with the Dopamine D3 Receptor. ACS Med Chem Lett. 2011; 2(4): 293-7.
94. Carlsson J, Coleman RG, Setola V, et al.: Ligand discovery from a dopamine D3 receptor homology model and crystal structure. Nat Chem Biol. 2011; 7(11): 769-78.
95. Godbole AA, Ahmed W, Bhat RS, et al.: Targeting Mycobacterium tuberculosis topoisomerase I by small-molecule inhibitors. Antimicrob Agents Chemother. 2015; 59(3): 1549-57.
96. Godbole AA, Ahmed W, Bhat RS, et al.: Inhibition of Mycobacterium tuberculosis topoisomerase I by m-AMSA, a eukaryotic type II topoisomerase poison. Biochem Biophys Res Commun. 2014; 446(4): 916-20.
97. Tan K, Cao N, Cheng B, et al.: Insights from the Structure of Mycobacterium tuberculosis Topoisomerase I with a Novel Protein Fold. J Mol Biol. 2016; 428(1): 182-93.
98. Nguyen ED, Norn C, Frimurer TM, et al.: Assessment and challenges of ligand docking into comparative models of G-protein coupled receptors. PLoS One. 2013; 8(7): e67302.
99. da Silveira NJ, Arcuri HA, Bonalumi CE, et al.: Molecular models of NS3 protease variants of the Hepatitis C virus. BMC Struct Biol. 2005; 5: 1.
100. Lee TV, Johnson RD, Arcus VL, et al.: Prediction of the substrate for nonribosomal peptide synthetase (NRPS) adenylation domains by virtual screening. Proteins. 2015; 83(11): 2052-66.
101. Anon. PEPI-TiDP23-C103: First-in-Human Study to Examine the Safety, Tolerability, and Plasma Pharmacokinetics of Increasing Single and Repeated Oral Doses of TMC558445 and of a Combined Single Day Dosing of Oral TMC558445 and Oral TMC310911 and Also Oral Darunavir. 2009.
102. Keck ZY, Enterlein SG, Howell KA, et al.: Macaque Monoclonal Antibodies Targeting Novel Conserved Epitopes within Filovirus Glycoprotein. J Virol. 2015; 90(1): 279-91.
103. Ferlenghi I, Clarke M, Ruttan T, et al.: Molecular organization of a recombinant subviral particle from tick-borne encephalitis virus. Mol Cell. 2001; 7(3): 593-602.
104. Zhang Y, Kaufmann B, Chipman PR, et al.: Structure of immature West Nile virus. J Virol. 2007; 81(11): 6141-5.
105. Kostyuchenko VA, Zhang Q, Tan JL, et al.: Immature and mature dengue serotype 1 virus structures provide insight into the maturation process. J Virol. 2013; 87(13): 7700-7.
106. Kostyuchenko VA, Chew PL, Ng TS, et al.: Near-atomic resolution cryo-electron microscopic structure of dengue serotype 4 virus. J Virol. 2014; 88(1): 477-82.
107. Zhang Y, Zhang W, Ogata S, et al.: Conformational changes of the flavivirus E glycoprotein. Structure. 2004; 12(9): 1607-18.
108. Scheffer IE, Baraitser M, Brett EM: Severe microcephaly associated with congenital varicella infection. Dev Med Child Neurol. 1991; 33(10): 916-20.
109. Deasy NP, Jarosz JM, Cox TC, et al.: Congenital varicella syndrome: cranial MRI in a long-term survivor. Neuroradiology. 1999; 41(3): 205-7.
110. Gatherer D: Zika virus protein structure homology modelling. 2016.
111. Anon. EMDataBank.
112. Sirohi D, Chen Z, Sun L, et al.: The 3.8 Å resolution cryo-EM structure of Zika virus. Science. 2016; 352(6284): 467-70.
113. Kostyuchenko VA, Lim EX, Zhang S, et al.: Structure of the thermally stable Zika virus. Nature. 2016; 533(7603): 425-8.
114. Song H, Qi J, Haywood J, et al.: Zika virus NS1 structure reveals diversity of electrostatic surfaces among flaviviruses. Nat Struct Mol Biol. 2016; 23(5): 456-8.
115. Tian H, Ji X, Yang X, et al.: The crystal structure of Zika virus helicase: basis for antiviral drug design. Protein Cell. 2016; 7(6): 450-4.
116. Anon: Zika Treatment Search Launched, Fueled By IBM's World Community Grid. 2016; [26th May 2016].
117. Andrade CH: Help an International Research Team Fight the Zika Virus. 2016; [26th May 2016].
118. Andrade CH, Perryman AL, Ekins S: OpenZika. 2016; [26th May 2016].
119. Trott O, Olson AJ: AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem. 2010; 31(2): 455-61.
120. Perryman AL, Yu W, Wang X, et al.: A virtual screen discovers novel, fragmentsized inhibitors of Mycobacterium tuberculosis InhA. J Chem Inf Model. 2015; 55(3): 645-59.
121. Perryman AL, Santiago DN, Forli S, et al.: Virtual screening with AutoDock Vina and the common pharmacophore engine of a low diversity library of fragments and hits against the three allosteric sites of HIV integrase: participation in the SAMPL4 protein-ligand binding challenge. J Comput Aided Mol Des. 2014; 28(4): 429-41.